Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAD versus IRD in newly diagnosed elderly frail multiple myeloma
ChiCTR1900024917Phase 4Completed
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ixazomib, doxorubicin, dexamethasone and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Beijing Jishuitan Hospital. Primary endpoints: M protein quantification, Bone marrow plasma cell percentage and 8 more. Started Jul 2019; status: completed.
02
Drugs
ixazomibdoxorubicindexamethasonelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900024917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024917.